1. INTRODUCTION 1.1. OVERVIEW OF THE GLOBAL POINT-OF-CARE TESTING MARKET 1.2. MARKET SEGMENTATION & COVERAGE 1.2.1. CURRENCY AND PRICING 1.2.2. LIMITATION 1.2.3. STAKEHOLDERS 2. RESEARCH METHODOLOGY 2.1. KEY TAKEAWAYS 2.2. ARRIVING AT THE GLOBAL POINT-OF-CARE TESTING MARKET SIZE 2.2.1. MARKET CRACKDOWN APPROACH 2.2.2. COMPANY REVENUE AND MARKET SHARE ANALYSIS 2.2.3. DATA TRIANGULATION 2.2.4. KEY DATA POINTS FROM PRIMARY SOURCES 2.2.5. PRODUCT PIPELINE ANALYSIS 2.2.6. PORTER’S FIVE FORCES MATRIX 2.3. GLOBAL POINT-OF-CARE TESTING MARKET: RESEARCH SNAPSHOT 2.4. ASSUMPTIONS 3. MARKET LANDSCAPE SUMMARY 4. PREMIUM INSIGHTS 4.1. OVERVIEW 4.2. GLOBAL POINT-OF-CARE TESTING MARKET: KEY PRIMARY INSIGHTS 4.3. MARKET OVERVIEW 4.3.1. DRIVERS 4.3.1.1. HIGH PREVALENCE OF INFECTIOUS DISEASES IN DEVELOPING COUNTRIES 4.3.1.2. INCREASING INCIDENCE OF LIFESTYLE DISEASES 4.3.1.3. RISING USAGE OF HOME-BASED POC DEVICES 4.3.1.4. GROWING NUMBER OF REGULATORY APPROVALS FOR NOVEL IMMUNOASSAY TECHNIQUES 4.3.1.5. SHORTAGE OF SKILLED LABORATORY TECHNICIANS INCREASING PREFERENCE OF POC TESTING 4.3.1.6. RISING INCIDENCE OF UNPLANNED PREGANANCIES 4.3.2. RESTRAINTS 4.3.3. OPPURTUNITIES 4.3.4. THREATS 4.4. KEY MARKET TRENDS AND UPCOMING TECHNOLOGIES 5. POINT-OF-CARE TESTING MARKET, BY TYPE 5.1. OVERVIEW 5.2. CARDIOMETABOLIC MONITORING KITS, BY PRODUCT TYPE 5.2.1. CARDIAC MARKERS 5.2.2. BLOOD GAS ELECTROLYTE TESTING KITS 5.2.3. HBA1C TESTING KITS 5.2.4. LIPID TESTING KITS 5.3. INFECTIOUS DISEASE TESTING KITS, BY PRODUCT TYPE 5.3.1. INFLUENZA TESTING KITS 5.3.2. HIV TESTING KITS 5.3.3. HEPATITIS C TESTING KITS 5.3.4. STD TESTING KITS 5.3.5. TROPICAL DISEASE TESTING KITS 5.3.6. HEALTHCARE ASSOCIATED INFECTIONS TESTING KITS 5.3.7. RESPIRATORY INFECTIONS TESTING KITS 5.3.8. OTHERS 5.4. CHOLESTROL TESTING KITS, BY PRODUCT TYPE 5.4.1. PROTHROMBIN TIME TESTING KITS 5.4.2. ACTIVATED CLOTTING TIME TESTING KITS 5.5. BLOOD GLUCOSE TESTING KITS 5.6. PREGNANCY AND FERTILITY TESTING KITS 5.7. TUMOR CANCER MARKERS 5.8. URINALYSIS TESTING KITS 5.9. HEMATOLOGY TESTING KITS 5.10. DRUGS OF ABUSE TESTING KITS 5.11. FECAL OCCULT TESTING KITS 5.12. RAPID COAGULATION TESTING KITS 5.13. OTHERS 6. POINT-OF-CARE TESTING MARKET, BY PRESCRIPTION MODE 6.1. OVERVIEW 6.2. PRESCRIPTION BASED TESTING KITS 6.3. OVER THE COUNTER (OTC) BASED TESTING KITS 7. POINT-OF-CARE TESTING MARKET, BY END-USER 7.1. OVERVIEW 7.2. HOSPITALS 7.3. CLINICS 7.4. AMBULATORY CARE 7.5. HOME HEALTHCARE 7.6. RESEARCH LABORATORY 8. POINT-OF-CARE TESTING MARKET, BY DISTRIBUTION CHANNEL 8.1. OVERVIEW 8.2. DIRECT TENDERS 8.3. RETAIL 9. POINT-OF-CARE TESTING MARKET, BY GEOGRAPHY 9.1. COUNTRYWISE POINT OF CARE TESTING MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY) 9.1.1. NORTH AMERICA 9.1.1.1. U.S. 9.1.1.2. CANADA 9.1.1.3. MEXICO 9.1.2. EUROPE 9.1.2.1. GERMANY 9.1.2.2. FRANCE 9.1.2.3. U.K. 9.1.2.4. ITALY 9.1.2.5. SPAIN 9.1.2.6. RUSSIA 9.1.2.7. TURKEY 9.1.2.8. BELGIUM 9.1.2.9. NETHERLANDS 9.1.2.10. SWITZERLAND 9.1.2.11. REST OF EUROPE 9.1.3. ASIA-PACIFIC (APAC) 9.1.3.1. JAPAN 9.1.3.2. CHINA 9.1.3.3. SOUTH KOREA 9.1.3.4. INDIA 9.1.3.5. AUSTRALIA 9.1.3.6. SINGAPORE 9.1.3.7. THAILAND 9.1.3.8. MALAYSIA 9.1.3.9. INDONESIA 9.1.3.10. PHILIPPINES 9.1.3.11. REST OF APAC 9.1.4. LATIN AMERICA 9.1.4.1. BRAZIL 9.1.4.2. REST OF LATIN AMERICA 9.1.5. MIDDLE EAST AND AFRICA 9.1.5.1. SOUTH AFRICA 9.1.5.2. REST OF MIDDLE EAST AND AFRICA 9.2. KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES 10. POINT-OF-CARE TESTING MARKET: COMPETITIVE LANDSCAPE 10.1. GLOBAL POINT OF CARE TESTING MARKET: COMPANY SHARE ANALYSIS 10.2. U.S. POINT OF CARE TESTING MARKET: COMPANY SHARE ANALYSIS 10.3. EUROPE POINT OF CARE TESTING MARKET: COMPANY SHARE ANALYSIS 10.4. APAC POINT OF CARE TESTING MARKET: COMPANY SHARE ANALYSIS 10.5. SOUTH AMERICA POINT OF CARE TESTING MARKET: COMPANY SHARE ANALYSIS 10.6. MEA POINT OF CARE TESTING MARKET: COMPANY SHARE ANALYSIS 10.7. MERGERS & ACQUISITIONS 10.8. NEW PRODUCT DEVELOPMENT & APPROVALS 10.9. EXPANSIONS 10.10. REGULATORY CHANGES 10.11. PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS 11. POINT-OF-CARE TESTING MARKET: COMPANY PROFILES 11.1. ABBOTT LABORATORIES, INC. 11.1.1 COMPANY OVERVIEW 11.1.2 SWOT ANALYSIS 11.1.3 REVENUE ANALYSIS 11.1.4 PRODUCT PORTFOLIO 11.1.5 RECENT DEVELOPEMENTS 11.1.6 DATA BRIDGE ANALYSIS 11.2. ROCHE DIAGNOSTICS LIMITED 11.2.1 COMPANY OVERVIEW 11.2.2 SWOT ANALYSIS 11.2.3 REVENUE ANALYSIS 11.2.4 PRODUCT PORTFOLIO 11.2.5 RECENT DEVELOPEMENTS 11.2.6 DATA BRIDGE ANALYSIS 11.3. SIEMENS AG 11.3.1 COMPANY OVERVIEW 11.3.2 SWOT ANALYSIS 11.3.3 REVENUE ANALYSIS 11.3.4 PRODUCT PORTFOLIO 11.3.5 RECENT DEVELOPEMENTS 11.3.6 DATA BRIDGE ANALYSIS 11.4. BECKMAN COULTER, INC. 11.4.1 COMPANY OVERVIEW 11.4.2 SWOT ANALYSIS 11.4.3 REVENUE ANALYSIS 11.4.4 PRODUCT PORTFOLIO 11.4.5 RECENT DEVELOPEMENTS 11.4.6 DATA BRIDGE ANALYSIS 11.5. BECTON, DICKINSON AND COMPANY 11.5.1 COMPANY OVERVIEW 11.5.2 SWOT ANALYSIS 11.5.3 REVENUE ANALYSIS 11.5.4 PRODUCT PORTFOLIO 11.5.5 RECENT DEVELOPEMENTS 11.5.6 DATA BRIDGE ANALYSIS 11.6. JOHNSON & JOHNSON 11.6.1 COMPANY OVERVIEW 11.6.2 SWOT ANALYSIS 11.6.3 REVENUE ANALYSIS 11.6.4 PRODUCT PORTFOLIO 11.6.5 RECENT DEVELOPEMENTS 11.6.6 DATA BRIDGE ANALYSIS 11.7. ALERE INC. 11.7.1 COMPANY OVERVIEW 11.7.2 SWOT ANALYSIS 11.7.3 REVENUE ANALYSIS 11.7.4 PRODUCT PORTFOLIO 11.7.5 RECENT DEVELOPEMENTS 11.7.6 DATA BRIDGE ANALYSIS 11.8. INSTRUMENTATION LABORATORY 11.8.1 COMPANY OVERVIEW 11.8.2 SWOT ANALYSIS 11.8.3 REVENUE ANALYSIS 11.8.4 PRODUCT PORTFOLIO 11.8.5 RECENT DEVELOPEMENTS 11.8.6 DATA BRIDGE ANALYSIS 11.9. PTS DIAGNOSTICS 11.9.1 COMPANY OVERVIEW 11.9.2 SWOT ANALYSIS 11.9.3 REVENUE ANALYSIS 11.9.4 PRODUCT PORTFOLIO 11.9.5 RECENT DEVELOPEMENTS 11.9.6 DATA BRIDGE ANALYSIS 11.10. ABAXIS, INC. 11.10.1 COMPANY OVERVIEW 11.10.2 SWOT ANALYSIS 11.10.3 REVENUE ANALYSIS 11.10.4 PRODUCT PORTFOLIO 11.10.5 RECENT DEVELOPEMENTS 11.10.6 DATA BRIDGE ANALYSIS 11.11. MEDTRONIC 11.11.1 COMPANY OVERVIEW 11.11.2 SWOT ANALYSIS 11.11.3 REVENUE ANALYSIS 11.11.4 PRODUCT PORTFOLIO 11.11.5 RECENT DEVELOPEMENTS 11.11.6 DATA BRIDGE ANALYSIS 11.12. ACCRIVA DIAGNOSTICS 11.12.1 COMPANY OVERVIEW 11.12.2 SWOT ANALYSIS 11.12.3 REVENUE ANALYSIS 11.12.4 PRODUCT PORTFOLIO 11.12.5 RECENT DEVELOPEMENTS 11.12.6 DATA BRIDGE ANALYSIS 11.13. OPTI MEDICAL 11.13.1 COMPANY OVERVIEW 11.13.2 SWOT ANALYSIS 11.13.3 REVENUE ANALYSIS 11.13.4 PRODUCT PORTFOLIO 11.13.5 RECENT DEVELOPEMENTS 11.13.5 DATA BRIDGE ANALYSIS 11.14. SIENCO, INC. 11.14.1 COMPANY OVERVIEW 11.14.2 SWOT ANALYSIS 11.14.3 REVENUE ANALYSIS 11.14.4 PRODUCT PORTFOLIO 11.14.5 RECENT DEVELOPEMENTS 11.14.6 DATA BRIDGE ANALYSIS 11.15. ALPHA SCIENTIFIC 11.15.1 COMPANY OVERVIEW 11.15.2 SWOT ANALYSIS 11.15.3 REVENUE ANALYSIS 11.15.4 PRODUCT PORTFOLIO 11.15.5 RECENT DEVELOPEMENTS 11.15.6 DATA BRIDGE ANALYSIS 11.16. ACCUBIOTECH CO. LTD. 11.16.1 COMPANY OVERVIEW 11.16.2 SWOT ANALYSIS 11.16.3 REVENUE ANALYSIS 11.16.4 PRODUCT PORTFOLIO 11.16.5 RECENT DEVELOPEMENTS 11.16.5 DATA BRIDGE ANALYSIS 11.17. ACON LABORATORIES, INC. 11.17.1 COMPANY OVERVIEW 11.17.2 SWOT ANALYSIS 11.17.3 REVENUE ANALYSIS 11.17.4 PRODUCT PORTFOLIO 11.17.5 RECENT DEVELOPEMENTS 11.17.6 DATA BRIDGE ANALYSIS 11.18. ACRONGENOMICS 11.18.1 COMPANY OVERVIEW 11.18.2 SWOT ANALYSIS 11.18.3 REVENUE ANALYSIS 11.18.4 PRODUCT PORTFOLIO 11.18.5 RECENT DEVELOPEMENTS 11.18.6 DATA BRIDGE ANALYSIS 11.19. BIOMÉRIEUX, BIOMERICA, INC. 11.19.1 COMPANY OVERVIEW 11.19.2 SWOT ANALYSIS 11.19.3 REVENUE ANALYSIS 11.19.4 PRODUCT PORTFOLIO 11.19.5 RECENT DEVELOPEMENTS 11.19.6 DATA BRIDGE ANALYSIS 11.20. ATLAS GENETICS LTD. 11.20.1 COMPANY OVERVIEW 11.20.2 SWOT ANALYSIS 11.20.3 REVENUE ANALYSIS 11.20.4 PRODUCT PORTFOLIO 11.20.5 RECENT DEVELOPEMENTS 11.20.6 DATA BRIDGE ANALYSIS 11.21. ALFA SCIENTIFIC DESIGNS, INC. 11.21.1 COMPANY OVERVIEW 11.21.2 SWOT ANALYSIS 11.21.3 REVENUE ANALYSIS 11.21.4 PRODUCT PORTFOLIO 11.21.5 RECENT DEVELOPEMENTS 11.21.6 DATA BRIDGE ANALYSIS 11.22. BIO-RAD LABORATORIES, INC. 11.22.1 COMPANY OVERVIEW 11.22.2 SWOT ANALYSIS 11.22.3 REVENUE ANALYSIS 11.22.4 PRODUCT PORTFOLIO 11.22.5 RECENT DEVELOPEMENTS 11.22.6 DATA BRIDGE ANALYSIS 11.23. MEDICA CORPORATION 11.23.1 COMPANY OVERVIEW 11.23.2 SWOT ANALYSIS 11.23.3 REVENUE ANALYSIS 11.23.4 PRODUCT PORTFOLIO 11.23.5 RECENT DEVELOPEMENTS 11.23.6 DATA BRIDGE ANALYSIS 11.24. NOVA BIOMEDICAL 11.24.1 COMPANY OVERVIEW 11.24.2 SWOT ANALYSIS 11.24.3 REVENUE ANALYSIS 11.24.4 PRODUCT PORTFOLIO 11.24.5 RECENT DEVELOPEMENTS 11.24.6 DATA BRIDGE ANALYSIS 12. APPENDIX 12.1. SOURCES AND BIBLIOGRAPHY 12.2. RELATED REPORTS 12.3. A GLIMSE OF DATA BRIDGE MARKET RESEARCH FACTBOOK 13. ABOUT DATA BRIDGE MARKET RESEARCH